Novel H3 receptor antagonists. Sulfonamide homologs of histamine

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 16, 1998, Pages 2157-2162

  Wolin, Ronald ^a   Connolly, Michael ^a   Afonso, Adriano ^a   Hey, John A ^a   She, Hoyan ^a   Rivelli, Maria A ^a   Willams, Shirley M ^a   West Jr , Robert E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE DERIVATIVE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; N METHYLHISTAMINE; PHOSPHINE DERIVATIVE; PHTHALIMIDE DERIVATIVE; SULFONAMIDE; ANTIHISTAMINIC AGENT; DRUG DERIVATIVE; HISTAMINE; PIPERIDINE DERIVATIVE; THIOPERAMIDE;

ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; GUINEA PIG; NONHUMAN; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; ANIMAL; BRAIN; CELL MEMBRANE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; KINETICS; METABOLISM; PHYSIOLOGY; SYNTHESIS;

ANIMALS; BRAIN; CELL MEMBRANE; DRUG DESIGN; GUINEA PIGS; HISTAMINE; HISTAMINE ANTAGONISTS; KINETICS; MOLECULAR STRUCTURE; PIPERIDINES; RECEPTORS, HISTAMINE H3; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0032543954     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00379-5     Document Type: Article

References (25)

1. 1. Black, J. W.; Duncan, W. A. M.; Durant, C. J.; Ganellin, C. R.; Parsons, M. E. Nature (London) 1972, 236, 385.
2. 2. (a) Arrang, J-M; Garbarg, M.; Schwartz, J-C. Nature (London) 1983, 302, 832.
3. (b) Timmerman, H. J. Med. Chem. 1990, 33, 4.
4. (c) Schwartz, J-C.; Arrang, J-M; Garbarg, M.; Korner, M. J. Exp. Biol. 1986, 124, 203.
5. 3. (a) Schlicker, E.; Betz, R.; Gothert, M. Naunyn-Schmeid. Arch. pharmacol. 1988, 337, 588.
6. (b) Schlicker, E.; Schunack, W.; Gothert, M.; Naunyn-Schmeid. Arch. pharmacol. 1992, 342, 497.
7. (c) Clapham, J.; Kilpatrick, G. J.; Br. J. Pharmacol. 1992, 107, 919.
8. 4. (a) Schwartz, J. C.; Arrang, J-M.; Garbarg, M.; Pollard, H. Agents Actions, 1990, 30, 13.
9. (b) Lipp, R.; Arrang, J-M.; Garbarg, M.; Luger, P.; Schwartz, J-C.; Schunack, W. J. Med. Chem. 1992, 35, 4434.
10. 5. Arrang, J-M.; Garbarg, M.; Lancelot, J.-C.; Lecomte, J-M.; Pollard, H.; Robba, M.; Schunack, W.; Schwartz, J.-C. Nature (London) 1987, 327, 117.
11. 6. (a) Ganellin, C. R.; Fkyerat, A.; Bang-Anderson, B.; Athmani, S.; Tertiuk, W.; Garbarg, M.; Ligneau, X.; Schwartz, J-C. J. Med. Chem. 1996, 39, 3806.
12. (b) Ganellin, C. R.; Hosseini, S. K.; Khalaf, Y. S.; Tertiuk, W.; Arrang, J-M.; Garbarg, M.; Ligneau, X.; Schwartz, J-C. J. Med. Chem. 1995, 38, 3342.
13. 7. Fell, N. H. U.S. Patent 2,372,066; May 22, 1945; Chem. Abstr. 1945, 39, 4722.
14. 8. Mor, M.; Bordi, F.; Silva, C.; Rivara, S.; Crivori, P.; Plazzi, P. V.; Ballabeni, V.; Caretta, A.; Barocelli, E.; Impicciatore, M.; Carrupt, P-A.; Testa, B. J. Med. Chem. 1997, 40, 2571.
15. 9. Vollinga, R. C.; Menge, W. M. P. B.; Leurs, R.; Timmerman, H. J. Med. Chem. 1995, 38, 266.
16. 10. A recent patent application from the James Black Foundation describing the use of sulfonamide and sulfamide derivatives prompted us to disclose our work in this area. Kalindjian, S.; Shankley, N.; Tozer, M.; McDonald, I.; Pether, M.; Harper, E.; Watt, G.; Cooke, T. International Application WO97/29092, August 14, 1997.
17. 11. (a) Sellier, S.; Buschauer, A.; Elz, S.; Schunack, W. Liebigs. Ann. Chem. 1992, 317.
18. (b) Griffith, R.K.; Dipietro, R.A. Synth. Commun. 1986, 16, 1761.
19. 12. Tsunoda, T.; Otsuka, J.; Yamamiya, Y.; Ito, S. Chem. Lett. 1994, 539 .
20. 3OD) δ 8.8 (s, 1H), 7.9 (d, 2H, J = 8.6 Hz), 7.7 (d, 2H, J = 8.6 Hz), 7.3 (s, 1H), 3.0 (t, 2H, J = 7.3 Hz), 2.8 (t, 2H, J = 7.5 Hz), 1.8 (m, 2H). 1.6 (m, 2H). MS (CI, M + H) 314.
21. α-methylhistamine as ligand.
22. 3 antagonists.
23. 16. Hey, J.A.; Prado, M.; Eagan, R.W., Kreutner, W.; Chapman. R.W. Eur. J. Pharmacol. 1992, 211, 421.
24. 17. Danko, G.; Hey, J.A.; Egan, R.W.; Kreutner, W.; Chapman, R.W. Eur. J. Pharmcol. 1994, 254, 283.
25. 50 value.